Neoantigen mRNA vaccines and A2A receptor antagonism: A strategy to enhance T cell immunity
Although neo-antigen mRNA vaccines are promising for personalized cancer therapy, their effectiveness is often limited by the immunosuppressive tumor microenvironment (TME). The adenosine A2A receptor (A2AR) inhibits dendritic cell (DC) function and weakens antitumor T cell responses through hypoxia...
Saved in:
Main Authors: | Saber Imani, Parham Jabbarzadeh Kaboli, Ali Babaeizad, Mazaher Maghsoudloo |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2458936 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy
by: Saber Imani, et al.
Published: (2025-01-01) -
Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II
by: Junjiang Fu, et al.
Published: (2025-01-01) -
Nuclear mRNA export
by: Chen Suli, et al.
Published: (2024-09-01) -
CleanCap M6 inhibits decapping of exogenously delivered IVT mRNA
by: Zachary F. Mandell, et al.
Published: (2025-03-01) -
Editorial: Glycobiology and glycosylation: deciphering the secrets of glycans in humans and pathogens
by: Parham Jabbarzadeh Kaboli, et al.
Published: (2025-02-01)